Home Angiogenesis FGFR inhibitor Lirafugratinib (RLY-4008)

research use only

Lirafugratinib (RLY-4008) FGFR2 Inhibitor

Cat.No.E1431

Lirafugratinib (RLY-4008) is an orally active and selective inhibitor of FGFR2.
Lirafugratinib (RLY-4008) FGFR inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 509.54

Jump to

Quality Control

Batch: E143101 DMSO]20 mg/mL]false]Ethanol]2 mg/mL]false]Water]Insoluble]false Purity: 99.01%
99.01

Solubility

In vitro
Batch:

DMSO : 20 mg/mL (39.25 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 2 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 509.54 Formula

C28H24FN7O2

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 2549174-42-5 -- Storage of Stock Solutions

Mechanism of Action

Targets/IC50/Ki
FGFR2
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04526106 Active not recruiting
FGFR2 Amplification|FGFR2 Gene Mutation|FGFR2 Gene Fusion/Rearrangement|FGFR2 Gene Translocation|FGFR2 Gene Activation|Intrahepatic Cholangiocarcinoma|Cholangiocarcinoma|Other Solid Tumors Adult
Relay Therapeutics Inc.
 September 2 2020 Phase 1|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map